Nap peptide for treatment of conditions related to a low level of sex hormone

NAP peptide addresses the need for hormone replacement alternatives by regulating UPR, effectively treating conditions related to low sex hormone levels, particularly in cases where traditional therapies are not feasible, offering a safe and effective treatment.

WO2026062663A1 Publication Date: 2026-03-26RAMOT AT TEL AVIV UNIVERSITY LTD
2 Cites 0 Cited by

Patent Information

Application Number
PCT/IL2025/050839
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-09-23
Filing Date
2025-09-21
Publication Date
2026-03-26

AI Technical Summary

Technical Problem

There is an unmet need for effective alternatives to hormone replacement therapy to mitigate the effects of low sex hormone levels or low sensitivity to said hormones in individuals, as existing therapies have off-target consequences and are contraindicated in many medical conditions.

Method used

The use of the NAP peptide (davunetide), a fragment of the activity-dependent neuroprotective protein (ADNP), to alleviate symptoms associated with low sex hormone levels by regulating the unfolded protein response (UPR), offering a hormone replacement therapy alternative.

Benefits of technology

NAP peptide effectively treats conditions related to low sex hormone levels, including those mediated by UPR, providing a safe and effective treatment option for conditions where hormone replacement therapy is contraindicated, reducing physical and emotional distress.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention provides methods for treating conditions, diseases or disorders associated with sex hormone imbalance and specifically with a low sex hormone level or response using NAP peptide, specifically conditions, diseases or disorders mediated via unfolded protein response.
Need to check novelty before this filing date? Find Prior Art